XML 23 R14.htm IDEA: XBRL DOCUMENT
v3.25.1

Discontinued Operations | 12 Months Ended
--- | ---
Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract] |
Discontinued Operations | 3. Discontinued Operations On February 20, 2025, the Company entered into the Share Purchase Agreement with AstraZeneca Treasury Limited, pursuant to which FibroGen and its subsidiary FibroGen China Anemia Holdings, Ltd. agreed to sell all of the issued and outstanding equity interests of FibroGen International to AstraZeneca Treasury Limited for an aggregate purchase price comprised of $85 million in cash for the enterprise value of FibroGen International, plus an additional cash amount equal to the net cash held in China by FibroGen International and its subsidiaries as of the closing. This sale includes all of our roxadustat assets in China, including FibroGen International’s subsidiary FibroGen (China) Medical Technology Development Co., Ltd and its 51.1% interest in Falikang. The transaction is expected to close by mid-2025, and is subject to customary closing conditions and closing deliverables, including receipt of regulatory approval from the China State Administration for Market Regulation. The Company analyzed the quantitative and qualitative factors and concluded that the sale of FibroGen International represents a strategic shift in FibroGen’s business and qualified as a discontinued operation. As a result, Company determined that FibroGen International met the “held for sale” criteria and the “discontinued operations” criteria in accordance with FASB ASC 205, Presentation of Financial Statements, as of December 31, 2024. Accordingly, the operating results related to the FibroGen International are classified as discontinued operations, and have been reflected as discontinued operations in the consolidated statements of operations, while the related assets and liabilities were classified within the consolidated balance sheets as held for sale for all periods presented. The financial results of the discontinued operations with respect to FibroGen International reflected in the consolidated statements of operations for the years ended December 31, 2024 and 2023 were as follows (in thousands):
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |
Revenue: |  |  |  |  |  |
Product revenue, net |  | $ | 173,664 |  |  | $ | 100,949 |
Operating costs and expenses: |  |  |  |  |  |
Cost of goods sold |  |  | 21,036 |  |  |  | 14,886 |
Research and development |  |  | 7,375 |  |  |  | 16,388 |
Selling, general and administrative |  |  | 32,304 |  |  |  | 28,769 |
Total operating costs and expenses |  |  | 60,715 |  |  |  | 60,043 |
Income from operations |  |  | 112,949 |  |  |  | 40,906 |
Interest and other, net |  |  |  |  |  |
Interest expense |  |  | (11,683 | ) |  |  | (7,437 | )
Interest income and other income (expenses), net |  |  | 423 |  |  |  | 2,886 |
Total interest and other, net |  |  | (11,260 | ) |  |  | (4,551 | )
Income before income taxes |  |  | 101,689 |  |  |  | 36,355 |
Provision for income taxes |  |  | 139 |  |  |  | 255 |
Investment income in unconsolidated variable interest entity |  |  | 3,969 |  |  |  | 2,638 |
Income from discontinued operations, net of tax |  | $ | 105,519 |  |  | $ | 38,738 |
The product revenue, net, consists primarily of revenues from sales of roxadustat commercial product to Falikang, a distribution entity jointly owned by AstraZeneca and FibroGen Beijing, and is discussed in the China Performance Obligation section in Note 4, Collaboration Agreements, License Agreement and Revenues. The carrying value of the assets and liabilities of the discontinued operations with respect to FibroGen International on the consolidated balance sheets as of December 31, 2024 and 2023 were as follows (in thousands):
|  | December 31, 2024 |  |  | December 31, 2023 |
Assets |  |  |  |  |  |
Cash and cash equivalents |  | $ | 51,696 |  |  | $ | 32,135 |
Accounts receivable, net |  |  | 18,443 |  |  |  | 7,432 |
Inventories |  |  | 15,547 |  |  |  | 24,392 |
Prepaid expenses and other current assets |  |  | 25,163 |  |  |  | 1,817 |
Total current assets held for sale |  |  | 110,849 |  |  |  | 65,776 |
Property and equipment, net |  |  | 7,041 |  |  |  | 8,341 |
Equity method investment in unconsolidated variable interest entity |  |  | 6,864 |  |  |  | 5,290 |
Operating lease right-of-use assets |  |  | 1,716 |  |  |  | 3,154 |
Other assets |  |  | 990 |  |  |  | 1,265 |
Total long-term assets held for sale |  |  | 16,611 |  |  |  | 18,050 |
Liabilities |  |  |  |  |  |
Accounts payable |  | $ | 26,974 |  |  | $ | 2,182 |
Accrued and other current liabilities |  |  | 10,679 |  |  |  | 39,904 |
Operating lease liabilities, current |  |  | 1,264 |  |  |  | 1,430 |
Total current liabilities held for sale |  |  | 38,917 |  |  |  | 43,516 |
Operating lease liabilities, non-current |  |  | 356 |  |  |  | 1,504 |
Total long-term liabilities held for sale |  |  | 356 |  |  |  | 1,504 |
The significant non-cash items and capital expenditures for the discontinued operations with respect to FibroGen International included in the consolidated statements of cash flows for the years ended December 31, 2024 and 2023 were as follows (in thousands):
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |
Depreciation |  | $ | 1,458 |  |  | $ | 2,559 |
Investment income in unconsolidated variable interest entity |  |  | (3,969 | ) |  |  | (2,638 | )
Dividend received from unconsolidated variable interest entity |  |  | 2,230 |  |  |  | 2,255 |
Stock-based compensation |  |  | 1,770 |  |  |  | 2,391 |
Purchases of property and equipment |  | $ | (357 | ) |  | $ | (859 | )
Included in the discontinued operations, Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. For the years ended December 31, 2024 and 2023, the net product revenue from sales to Falikang were $159.0 million and $89.1 million, respectively. The other income from Falikang were immaterial for the years ended December 31, 2024 and 2023. For the years ended December 31, 2024 and 2023, the investment income (loss) in Falikang was $4.0 million and $2.6 million, respectively. During the years ended December 31, 2024 and 2023, the Company received $2.2 million and $2.3 million of dividend distribution from Falikang, respectively. As of December 31, 2024 and 2023, the Company’s equity method investment in Falikang were $6.9 million and $5.3 million, respectively, which was included in the long-term assets held for sale on the consolidated balance sheets. As of December 31, 2024 and 2023 accounts receivable, net, from Falikang were $13.9 million and $5.2 million, respectively.

X
- References No definition available. + Details
Name: | us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details
Name: | us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration